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The recent changes in the classification of female sexual dysfunction in the 5th edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the U.S. Food and 
Drug Administration’s (FDA) approval of the first drug to treat low sexual desire in 
women (Flibanserin) have both sparked significant debate among clinicians and 
researchers. We first discuss the rationale for the DSM changes and outline the DSM-5 
criteria for Female Sexual Interest/Arousal Disorder. We provide an overview of some 
of the key events leading up to the approval of Flibanserin for the treatment of 
hypoactive sexual desire disorder in women and highlight the role of the “Even the 
Score” advocacy campaign, that accused the FDA of gender bias in not giving women 
with sexual desire problems access to treatment options. Incorporating narratives from 
testimonials of female patients attending the 2014 FDA Patient-Focused Drug 
Development Public Meeting, we examine some of these women’s prevalent beliefs 
around sexual “normalcy” and the immutability of sexual desire. We critique how the 
media and pharmaceutical companies depict sexual norms and female sexual desire and 
how pharmaceutical trials often narrowly defines and assesses sexual desire and “sex.” 
We end with some recommendations for how researchers, clinicians, and journalists 
can better acknowledge that sex and desire have multiple meanings and interpretations 
with a view to women being offered a truly informed choice concerning their sexual 
health. 
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Historical aspects of the classification of female sexual dysfunction  
 The concept of “psychosexual dysfunction” first appeared in the third edition of 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) (American Psychiatric 
Association (APA), 1980). The first two versions of the DSM did not include sexual 
disorders, although “frigidity” and vaginismus were listed in a section on 
“supplementary terms of the urogenital system” in DSM-I (APA, 1952). DSM-II included 
dyspareunia as an example of a “psychophysiologic genitourinary disorder in which 
emotional factors play a causative role.” (APA, 1968, p. 47). Based on the Human Sexual 
Response Cycle (HSRC) developed by Masters and Johnson (1966), and later expanded 
to include the desire phase (Kaplan, 1974), a number of psychosexual dysfunctions 
were introduced in DSM-III (1980), including “inhibited sexual desire” (APA, 1980). In 
DSM-IV the terminology related to “inhibition” disappeared but psychosexual disorders 
were still organised around the HSRC model and defined as “disturbances in sexual 
desire and in the physiological changes that characterize the sexual response cycle” 
(APA, 1994, p. 493). An inherent feature of the HSRC is that it proposes a universal, 
linear series of ‘phases’ of sexual response – excitement, arousal, orgasm, and resolution 
– that are essentially the same in women and men. In DSM-IV-TR the essential criterion 
for Hypoactive Sexual Desire Disorder (HSDD) was identical for women and men: 
“persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual 
activity” that causes “marked distress or interpersonal difficulty” (APA, 2000, p. 498). 
In the last two decades many critiques of both the HSRC and the DSM-IV 
classification have been put forward (Boyle, 1994; Tiefer, 1991, 2001). Criticisms of 
DSM-IV included an over-emphasis on genital response, inadequate acknowledgment of 
relationship and partner factors, and the lack of any defined severity or duration 
criteria (Graham, 2010; Mitchell & Graham, 2008; Tiefer, 1991). The latter criticism is 
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supported by the fact that many epidemiological surveys have reported extremely high 
prevalence rates for sexual “dysfunction” e.g., the highly cited figure that 43% of 
American women have a “sexual dysfunction” (Laumann, Paik, & Rosen, 1999). Surveys 
that included more stringent severity criteria and assessed individuals’ distress about a 
sexual problem have consistently produced much lower prevalence rates (Hayes, 
Dennerstein, Bennett, & Fairley, 2008; Mitchell et al., 2013, 2015; Oberg, Fugl-Meyer, & 
Fugl-Meyer, 2004; Witting et al., 2008). For example, in the recent U.K. NATSAL-3 
survey, among sexually active women aged 16-74, the one year population prevalence 
estimate of “lack of interest and arousal” was 6.5%, but after applying severity, (6 
months or more), duration, (always/very often symptomatic) and distress criteria 
(fairly/very distressing), the estimate dropped to 0.6% (Mitchell et al., 2015). 
After the publication of DSM-IV-TR (2000), a number of consultation groups and 
consensus panels proposed revisions to the DSM classification system (e.g., Basson et 
al., 2000, 2003; Lue et al., 2004). With the exception of the New View classification 
system (Kaschak & Tiefer, 2001), however, most of the revisions recommended were 
minor and maintained the HSRC structure of the DSM (Bancroft, Graham, & McCord, 
2001). 
The 5th. edition of DSM (APA, 2013) comprised major changes in the 
classification of sexual disorders, particularly for female sexual disorders (Graham, 
2016). Firstly, the diagnostic categories no longer map onto Masters and Johnson’s  
HSRC phases. The revised definition of sexual dysfunction in DSM-5 reflects this: “a 
group of disorders that are typically characterized by a clinically significant disturbance 
in a person’s ability to respond sexually or to experience sexual pleasure.” (APA, 2013, 
p. 423). Secondly, specific duration and severity criteria were added to all of the sexual 
dysfunctions: a requirement that the symptoms must have persisted for a minimum 
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duration of approximately six months and have been experienced on all or almost all 
(approximately 75-100%) of sexual encounters. As in DSM-IV, there is also a 
requirement that the symptoms cause “clinically significant distress in the individual.” 
The introduction of more stringent severity and duration criteria was an attempt to 
distinguish between transient difficulties and more persistent, distressing problems and 
to “raise the bar” for diagnosis (Graham, Brotto, & Zucker, 2014). 
Regarding desire and arousal–related disorders, both the Female Sexual Arousal 
Disorder and the HSDD diagnoses were deleted and one new disorder – Female Sexual 
Interest/Arousal Disorder (FSIAD) – was added in DSM-5. Qualitative, experimental and 
clinical studies, including research on the incentive motivation model (Laan & Janssen, 
2007) had demonstrated no empirical basis for any distinction between subjective 
arousal and desire (Laan & Both, 2008; Meana, 2010) (for more a detailed justification 
for the DSM-5 changes, see Brotto, 2010; Graham, 2010, 2016). The criteria for low 
sexual desire/arousal were expanded in FSIAD to include subjective, behavioral, and 
physical aspects of desire/arousal. A polythetic approach was adopted: to meet criteria, 
a woman needs to meet three of six possible criteria: (1) absent/reduced interest in 
sexual activity; (2) absent/reduced sexual/erotic thoughts or fantasies; (3) no/reduced 
initiation of sexual activity and typically unresponsive to a partner’s attempts to initiate; 
(4) absent/reduced sexual excitement/pleasure during sexual activity on all or almost 
all…sexual encounters; (5) absent/reduced sexual interest in response to any internal 
or external sexual/erotic cues (e.g., written, verbal, visual); (6) absent or reduced 
genital or nongenital sensations during sexual activity on all or almost all…sexual 
encounters (APA, 2013, p. 433). A polythetic approach was chosen to recognize the fact 
that women do not experience desire/arousal problems in a uniform way (Brotto, 
Graham, Paterson, Yule, & Zucker, 2015). Many studies have demonstrated both 
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women’s (Giles & McCabe, 2009; Sand & Fisher, 2007) and men’s  (Connaughton, 
McCabe, & Karantzas, 2016; Giraldi, Kristensen, & Sand, 2015) sexual experiences do 
not fit any “one size fits all” model of sexual response. 
Some authors have asserted that the FSIAD diagnosis (Giraldi et al., 2015; 
Spurgas, 2016) replaces the HSRC model as a framework for DSM categories with 
Basson’s (2000) circular model of sexual response, which emphasizes the role of 
“responsive” sexual desire rather than so-called “spontaneous” desire. However, as 
discussed above, in developing the polythetic new criteria for FSAID no one model of 
sexual response was privileged and, unlike DSM-IV, the criteria allow for the fact that 
there is variability in how sexual interest/arousal problems may be expressed. Other 
critics have expressed concern that the new criteria will mean that some women who 
would have met criteria for a DSM-IV diagnosis would no longer do so and would be 
excluded from treatment (Derogatis, Clayton, Rosen, & Pyke, 2011). It seems that this 
concern is largely about the impact that revised diagnostic criteria would have on the 
development and approval of pharmaceutical treatment for women with low desire 
(Brotto, Graham, Binik, & Segraves, 2011).  
Pharmaceutical Treatments for Women’s Low Sexual Desire 
In parallel with the criticisms of the DSM classification of sexual dysfunction, 
there has also been a longstanding critique about the growing medicalization of 
sexuality (Bancroft, 2001; Moynihan, 2003; Tiefer, 2001) that “prescribes and 
demarcates sexual interests and activity, defining normality and deviance in the 
language of sexual health and illness” (Tiefer, 2001, p. 65). After the approval in 1998 of 
Sildenafil (Viagra®) for men, there were sustained efforts by pharmaceutical companies 
to find a “female Viagra” (see Table 1 for a timeline of these developments). Creating a 
market for sexual pharmaceuticals for women included promoting the idea that Female 
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Sexual Dysfunction (“FSD”) was a serious public health concern and an unmet treatment 
need; CME workshops, professional meetings and media all contributed to this process 
(Cacchioni, 2015). 
Initial trials of the use of Sildenafil for Female Sexual Arousal Disorder proved 
disappointing and in 2004 Pfizer discontinued their clinical trials of Viagra® for women 
with arousal disorders (Mayor, 2004), citing the fact that “men and women have a 
fundamentally different relationship between arousal and desire” (Harris, 2004). 
Attention turned to treatment of low sexual desire, with attempts to gain FDA approval 
for Intrinsa,® a testosterone patch for treatment in surgically menopausal women, and 
Libigel®, a transdermal testosterone gel, for postmenopausal women with HSDD. In the 
case of Intrinsa®, concerns over whether efficacy outweighed the safety risks led the 
FDA to reject the drug (although it was approved in 2005 by the European Medicines 
Agency, the European counterpart of the FDA). Libigel® was not approved by the FDA 
because of poor clinical efficacy data. Other drugs to treat women’s desire problems are 
also in development; for example, subcutaneously administered Bremelanotide, a 
melanocortin agonist, a treatment for FSAD and HSDD, is now in Phase III trials 
(http://www.palatin.com/products/bremelanotide.asp). Lybrido, containing 
testosterone and Sildenafil, and Lybridos, containing testosterone and buspirone, are 
other drugs intended to treat HSDD in women which are still at the stage of Phase III 
trials. 
Flibanserin and the Even the Score Campaign 
The first medication to receive FDA approval for the treatment of HSDD in 
premenopausal women was Flibanserin (Addyi®) in 2015 (see Table 1 for timeline). 
Flibanserin is a drug with mixed effects on serotonergic and dopaminergic transmitter 
systems that was originally tested as an antidepressant but was ineffective (Basson, 
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Driscoll, & Correia, 2015). In 2010 the FDA rejected Boehringer Ingelheim’s application 
for approval because of lack of clinical efficacy in two phase 2 trials. Sprout 
Pharmaceuticals then acquired the drug and re-applied for FDA approval in 2013 with 
data from a third trial, but again the FDA did not grant approval, citing safety concerns, 
which included somnolence, hypotension, and syncope, and limited efficacy.  
The final, and successful, FDA application for the drug was submitted in 2015. 
Interestingly, this application contained no additional efficacy data and only limited 
additional safety data (Woloshin & Schwartz, 2016). For example, concerns about 
possible interactions of Flibanserin with alcohol were addressed with a study of 23 men 
and 2 women. The drug received approval for the treatment of HSDD in premenopausal 
women in August 2015, but with a “black box warning”, the most serious FDA safety 
alert and the inclusion of risk evaluations and mitigation strategies (REMS), requiring 
prescriber and pharmacy certification to prescribe the medication. Although Flibanserin 
was only approved for pre-menopausal women, many have argued that it will almost 
certainly be used “off-label” e.g., among women who are post-menopausal, women with 
health conditions who were excluded from the trials (Gellad, Flynn, & Alexander, 2015). 
Since approval of the drug, the first systematic review and meta-analysis on the 
impact of Flibanserin in women with HSDD was published (Jaspers et al., 2016). The 
findings suggested that the benefits of Flibanserin treatment are “marginal,” 
particularly when taking into account the significant occurrence of adverse events. The 
authors concluded that treatment with the drug resulted, on average, in one-half 
additional “sexually satisfying event” per month and clinically increased the risk of 
dizziness, somnolence, nausea, and fatigue.  
One notable difference from the earlier unsuccessful applications was that in the 
year leading up to FDA approval there was a concerted advocacy campaign (“Even the 
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Score”), including some women’s health organizations, health professionals and 
patients, and backed by Sprout Pharmaceuticals. The group’s purpose was to increase 
awareness of HSDD and to address what it considered a “persistent gender inequality” 
within the FDA regarding treatments for sexual dysfunction. Over the course of the 
campaign, the petition garnered more than 60,000 signatures. Even the Score argued 
that the FDA had approved 26 drugs marketed for male sexual dysfunction, compared 
to zero for women. This claim was misleading; there are no approved medications for 
low sexual desire for men and most of the 26 drugs are different formulations of 
testosterone. The Even the Score online campaign gathered momentum in the months 
leading up to the first Patient Focused Drug Development meeting held at the FDA in 
October, 2014, with letters of support from congresswomen and some women’s 
organizations (Tiefer, Laan, & Basson, 2015). Even the Score supporters were present 
and testified at both FDA Advisory Committee meetings prior to approval of the drug, 
wearing #WomenDeserve badges (see Table 1). Below we present some of the 
narratives from the patients who presented at the FDA-organized October 2014 Patient-
Focused Drug Development meeting. 
Women’s Narratives and the FDA-Sponsored Patient-Focused Drug Development 
Public Meeting 
On October 27th 2014, the Food and Drug Administration (FDA) held a public 
meeting to hear testimonials from women with FSD. Of the eight women on the patient 
panels, five had their travel to the meeting arranged and paid for by Veritas 
Pharmaceuticals. One panel member stated her travel expenses had been paid for by 
Veritas Pharmaceuticals through grants from Sprout Pharmaceuticals, Even the Score, 
and the Institute for Sexual Medicine. A further seven out of the twelve non-panel 
members who gave testimonials received the same. This information is not highlighted 
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to suggest that the women were blindly driven by pharmaceutical company motives, 
but the source of funding has to be taken into account when assessing the extent to 
which the group of women who gave testimonials are representative of women with 
sexual problems. It is also worth noting that all but one of the women who gave 
testimonials – both those who had paid for their own travel and those who received 
funding from Veritas Pharmaceuticals – had requested pharmaceutical treatment for 
FSD. All had sought pharmaceutical treatment (predominantly testosterone treatment), 
some were still taking it, and others had stopped due to side effects and lack of efficacy. 
Two women had participated in the Flibanserin clinical trials, describing themselves as 
“devastated” when the trials ended. During the trials, both described dramatic effects on 
their sexual desire:  
“Going from no thoughts during the day and really no desire, no initiation to 
suddenly…I'd text him in the middle of the day and get a flutter and I did not mean in 
my heart…I began initiating where I had not in a long time.”1 
“Within a couple of weeks [of being on the trial] my feelings had changed dramatically. I 
had sexual feelings which I had not felt in many, many years. I was the one initiating sex, 
much to the surprise of my husband and the experiences were very pleasurable.” 
Other women as ones described similar feelings. Women talked of wanting to be 
“the woman my husband married not too long ago” and feeling guilty that their desire 
for their partners was no longer the same as it was when their relationship began. One 
woman described this guilt as feeling like “I pulled a bait and switch with my poor 
husband who is undoubtedly wondering where the old me has run off to.” 
                                                        




Wanting to return to the level of sexual desire they experienced earlier in their 
relationships is a wish that runs through all of the women’s testimonials, whether or not 
they had explored and/or received treatment. During their testimonials, the women 
spoke of wanting “the closeness, the feeling of well-being that comes with the 
passionate, satisfying sexual relationship,” and “to want to want it all the time; I want to 
always desire my husband and I don't want it to be situational…and for it to not cause 
distress.” 
As one woman described it: “Sex is not just about orgasm. I mean a successful or 
satisfying event for me is more about feeling connected [to my husband] and being close 
and feeling arousal…it is not an issue of being able to have sex because I can perform 
any time. The difference in desire is that comes from within and that makes me feel 
alive and like a woman and desirable and feminine”. 
Lacking such desire, women spoke of feeling “dead inside” and “less of a woman”, 
as though “my body was like a shell with nothing inside”. For some this lack affected 
every aspect of their lives, forcing them to structure their lives around it. Some spoke of 
effects on familial relationships and friendships; others told of its impact on their work 
lives; one woman, in particular, recounted effects on her ability to concentrate and deal 
with colleagues. Inevitably, many women reported that their loss of desire had 
impacted their relationships with their partners. Many felt guilty for rebuffing attempts 
by their partners to initiate sex, some avoiding any situations with the potential for 
these attempts by, for example, going to bed after their partners and getting up before 
they woke. This guilt led others to report engaging in what they referred to as “duty 
sex,” an activity they defined as having sex with their partners out of obligation rather 
than for pleasure. 
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Ageing, childbirth, hysterectomy, breast cancer, mastectomy, the stresses of 
raising children, working full time, fatigue, and side effects from medication, both for 
FSD and other conditions, though included in the women’s testimonials, seemed to be 
dismissed by the women themselves as possible causes or contributors to their lack of 
desire. There is a sense that the women felt that desire should remain unaffected by 
anything outside of the bedroom, from the stresses of everyday life to the trauma of 
cancer. This isolates desire and raises the question of what part the women 
expect/want it to play in their lives. All of the women described their lack of desire in 
physiological terms and in the context of sexual interactions with their partners: they 
referred to their partners being understanding, knowing when their testosterone 
pellets needed to be replaced because their desire level would drop, discussing their 
low libido, and having intercourse to please their partner despite it giving them no 
pleasure. The women frequently referred to their previous sex lives (when they had 
sexual desire) as “normal.” Without speaking to the women to clarify their definition of 
“normal,” it is not possible to ascertain whether they meant normal for them or what 
they considered normal based on cultural cues.  
The subject of sexual normalcy on a cultural level was raised by the one woman 
who was not seeking a pharmaceutical treatment. Her concern over her loss of libido 
had taken her away from “the pathological” to an exploration of her relationship with 
her husband and her own feelings about desire. As she explained it: 
“I really thought I had lost something. I was resigned to the idea that sex was going to be 
a drag for the rest of my life. As I began my process I went down some of the common 
paths of pathology…Once I decided I didn't want to live a sexually repressed life I 
started finding information that would be helpful to me…What I would look for in an 
ideal treatment for my lack of desire is a broader definition of normal sexuality for both 
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sexes. I would appreciate a movement away from a culturally driven definition of 
normal that creates distress and anxiety in people when they don't think they are living 
up to an ideal. I think there are all kinds of reasons people don't relax sexually in their 
relationships and it is much more complex than physical diagnosis and physical 
treatments. It is my personal opinion that treatments that allow for sexual difference 
account for the human waxing and waning of physical and sexual desire and arousal and 
focus on relationship work in general would be most helpful. Where to go from there is 
more a question for each person than it is finding an answer for all.” 
The women attended the meeting to discuss their sexual difficulties, their hopes 
for treatment choices, their attempts to obtain treatment, and their belief that they have 
a right to sexual health. However, their dismissal of potential contributors other than 
the physiological echoes a medicalised approach to sex encouraged by physicians to 
whom a number of the women said they had received treatment. The women spoke of 
wanting choices of treatment and their hope that the approval of a drug to treat FSD 
would provide them with that. However, that choice would be restricted by the efficacy 
of the drug and potential side effects (as witnessed by Flibanserin). 
The meaning of ‘sex’ in research on women’s sexual desire 
 Within research and clinical work it is standard practice to operationalize 
definitions and clearly understand the meanings of terminologies to be certain all 
involved– participants, researchers and wider audiences – will follow and agree upon 
descriptors used to gather research data and latterly interpret findings. Thus, it would 
be expected for terms like “sex” to be specifically defined, not least because the term has 
multiple meanings and understandings across cultures, genders, sexualities and history 
(Carpenter, 2001; Jutel, 2010; Pitts & Rahman 2001; Sanders & Reinisch, 1999; Sanders 
et al., 2010). If this does not happen it is difficult to draw reliable conclusions from 
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studies. While this remains a problem across sexological research and is mirrored in 
much mainstream media coverage and the self-help market (Attwood, Barker, Boynton, 
& Hancock, 2015), it is particularly a problem in pharmaceutical trials of treatments for 
low sexual desire in women (Angel, 2012; Moynihan & Mintzes, 2010). 
Where terminologies are not defined, it is unclear when participants are asked 
about “sex” and “desire,” what they are recalling or recording when they respond to 
open or closed research questions. “Sex” for participants in research (and society more 
generally) might include giving/getting masturbation, oral or anal sex; or other 
activities including fantasy and role-play, BDSM, or other pleasurable touch. By not 
measuring all possible means of enjoying “sex” (or letting participants clearly self 
define) there is limited scope for noting exactly where “problems” with desire/orgasm 
may exist, while still perpetuating the idea that the only valid means of having sex and 
orgasm is through PIV intercourse (Angel, 2010; Moynihan & Mintzes, 2010; Wood, 
Mansfield, & Koch, 2006).  This is problematic as it limits both what might be deemed as 
sex for participants and creates hierarchies where “proper” sex is penetrative and goal-
focused with the end aim of it being the “achievement” of orgasm. Participants who may 
well experience desire, pleasure or orgasm through non-PIV activities do not have scope 
to record those activities and may well be categorized as dysfunctional as a 
consequence. Moreover, in setting up “normal” sex as a quantitative, PIV penetrative 
activity, options for exploring pleasure as reported via the media, sex education or 
research are limited so people who may well benefit from having additional means to 
enjoy sexual pleasure are not informed of their choices (see Attwood et al., 2015; Frith, 
2015). In turn this creates both a means of problematizing desire, defining ‘normality’ 
and offering solutions to fix those who do not fit the following representations of sex 
and relationships. 
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Looking at the publicity materials for Even the Score, press releases (and coverage) 
for Flibanserin/Addyi®, subsequent media coverage, the testimonies given at the FDA 
hearings (see above), and the content of pharmaceutically funded Continued Medical 
Education courses and materials, the following themes emerge around how sex is 
represented (see also Frith, 2015; Fishman & Mamo, 2002; Meana, 2010; Moynihan & 
Mintzes, 2015): 
 “Desire” is strong and spontaneous rather than reactive and responsive. 
 Orgasms are goals to be achieved. 
 “Sex” is taken to mean penis in vagina intercourse. And “good” or “healthy” sex 
requires frequent and novel sexual experiences.  
 While other sexual activities [including but not limited to kissing, cuddles, 
massage; sharing fantasies; talking about, reading or watching erotica/porn; 
mutual or solo masturbation; giving or receiving oral sex (including oral or 
analingus); using sex toys; BDSM; role play; anal intercourse] may be mentioned 
these are not commonly included in research on female sexual desire problems. 
They are presented as precursors or inferior alternatives to penis in vagina 
intercourse. 
 Life events should not intrude into the regular schedule of having sex. 
 (Frequent) Sex is the “glue” that holds relationships together. 
 Sex is a vital, healthy/healthful and central part of any relationship. 
 Male desire and orgasm is uncomplicated and ever-present, women’s desire and 
orgasm are complex, elusive and difficult/time consuming to “achieve.”  
Publicity around developing drugs for women has rehearsed themes that at times 
are ahistorical and inaccurate. These include reclaiming feminist narratives with 
arguments like “my turn now” or “my right” to medication (Goldstein, 2009), usually 
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paired with the erroneous , discussed above, that there are 26 drugs for men but none 
for women.  Alongside this are easily disprovable claims that women have historically 
been neglected from or understudied in sex research (Hall, 2003). These of 
accompanied by “choice” based arguments: women ought to have the right to choose 
drugs that might overcome sexual problems, if such drugs are available and where 
drugs are available, women would be able to weigh up any possible risks associated 
with any medication. This argument is problematic given how women are not offered 
informed choices and information about drugs nor alerted to the limitations and biases 
of existing studies, side effects, and alternatives that could be attempted to boost desire 
or enjoy sex more are not also explained.  
Rather than seeing “sex” as varied and diverse – and desire in a similar way – and 
noting the varied, legitimate, reasons women may not desire sex (Brotto, 2010) 
pharmaceutically funded trials and associated press coverage report women who do not 
desire “sex” as having a clinical problem requiring a medical solution (Angel, 2010, 
2012; Moynihan & Mintzes, 2015). 
Additional problems with media 
While the combination of sex and science proves consistently inviting to the 
press, the treatment of stories around FSD has included setting up false debates (e.g., 
should women be allowed drugs for desire? – yes/no) or framing complex discussions 
as two sided accounts. Whether it is due to time pressures, a lack of scientific 
understanding or a lack of awareness about the history of drugs in this area, press 
coverage has tended to be uncritical around key terms, identifying conflict of interest, or 
addressing core issues of trial design or safety/efficacy of drugs (Attwood et al., 2015; 
Moynihan & Mintzes, 2015).  
Limits of research – women not like us 
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Alongside difficulties of defining key terminologies, the drug trials for FSD 
pharmaceuticals have been limited by who participated in the research. Studies (e.g. 
Katz et al., 2013; Goldfischer et al., 2011; Simon et al., 2014) have centred around 
heterosexual, Western (commonly American) middle aged, and women in monogamous, 
long-term relationships (cohabitation or marriage). Single women, younger and older 
women (under 30 and over 60), black and other ethnic minority women, and lesbian, bi 
and Trans women are either unrepresented or excluded from trials. It is unwise to draw 
conclusions about the sexual lives and desires of all women globally from these studies 
(Moynihan & Mintzes, 2015). In some cases, however, trials that are primarily about 
drugs to boost desire in women have not included women at all. For example, as 
discussed above, the additional safety trials required for Addyi on the interaction 
between alcohol use and the drug included a sample of only 25 participants, 23 of 
whom were men.  
Limitations of trials 
While it is common for drug trials to be tested against placebo, it would be useful in an 
area where there are multiple factors that might influence desire to test drugs against 
other kinds of intervention. For example, desire-enhancing drugs could be tested 
against sex education, using sex toys and/or lubricant, relationship therapy, or 
confidence/assertiveness courses. 
Recommendations 
 We have several recommendations for researchers, clinicians, and journalists. 
Regarding research and clinical work, there is a pressing need for better definitions and 
assessments that acknowledge that sex and desire have multiple meanings and 
interpretations. Although qualitative research on women’s sexual experience has 
increased in the last decade, we still understand little about what terms such as “desire” 
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or “distress” about lack of desire mean to women themselves. There also needs to be a 
better acknowledgment by researchers of the variability of women’s sexual experiences. 
More research is required on the experiences of women from different cultures and of 
different ages, ethnicities, and sexual orientation, all of whom have been under-
represented, particularly in pharmaceutical trials. 
 Regarding the media, more comprehensive and critical coverage is needed, 
where the history, conduct, and outcomes of trials (including limitations and side 
effects) are noted. Media articles should also acknowledge where previously “hyped” 
trials were discontinued or where treatments were not approved. Any potential 
conflicts of interest of researchers involved in trials should be declared (as they are in 
scientific journal articles). This is challenging in the fast-paced media environment 
where journalists are often not trained or supported to find, critique, and explore 
research, especially in the area of “sex science,” where correspondents covering stories 
are not trained science reporters.  As an addition to writing this paper we are creating 
guidance for journalists in how to cover sex research and further training for the media. 
 In conclusion, while the “Even the Score” campaign used the slogan that women 
have the right to make their own “informed choices” concerning their sexual health, we 
believe that to offer women a truly informed choice means more than making safe and 
effective drug treatments for low desire available. Women should also be reassured that 
transient (and often adaptive) reductions in sexual desire are not evidence of 
“dysfunction” and informed of the many non-pharmacological approaches to enhancing 
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Table 1. Timeline. 
DATE EVENT(S) CITED IN/BY 
1999 Journal of the American Medical 
Association publishes research 
claiming 43% US women and 31% 
men have a sexual dysfunction.  
 
Invitation-only pharmaceutical 
conference ‘New Perspectives in the 
management of sexual dysfunction,’ 
Boston.  
Laumann, Paik, & Rosen (1999) 
Sexual dysfunction in the 




Tiefer (2006) Female Sexual 
Dysfunction: a case study of 
disease mongering and activist 
resistance.  
 
Moynihan (2005). The 
marketing of a disease: Female 
sexual dysfunction.  
2000 FDA Approves Eros Clitoral Therapy 
Device 
Proctor and Gamble begin trials of 
Intrinsa (testosterone patch) 
Second Boston Conference ‘New 
perspectives in the management of 
sexual dysfunction’ 
FDA issue draft guidelines for 
Tiefer (2006) ibid. 
 29 
research protocols on drug 
development for Female Sexual 
Dysfunction (FSD). As yet these 
guidelines have not been formalised. 
New View Campaign launched 
2001 Pfizer begins sponsoring Continued 
Medical Education (CME) courses on 
Female Sexual Dysfunction. 
International Society for the Study 
of Women’s Sexual Health (ISSWSH) 
launched, followed by regular local 
meetings and annual conferences. 
Tiefer (2006) ibid. 
2002   
2003 Non drug company funded research 
from the UK finds far lower levels of 
reported FSD and desire. Problems 
clearly linked to mental or physical 
health problems or 
relationship/cultural factors. 
Nazareth, Boynton, & King 
(2003) Problems with sexual 
function with people attending 
London general practitioners: 
cross sectional study.  
Mercer et al. (2003) Sexual 
function problems and help 
seeking behaviour in Britain: 
national probability sample 
survey.  
2004 Drug trials by Pfizer on Viagra for  
 30 
women are discontinued. 
Proctor and Gamble file drug 
application for Intrinsa (see above) 
for surgically menopausal women 
who have Hypoactive Sexual Desire 
Disorder. Application withdrawn 
when FDA raise concerns over risks 
of breast cancer and coronary heart 
disease outweighing benefits of 
drugs. Proctor and Gamble begin 
funding CME courses on FSD. 
New View CME course launched on 
Medscape 
2005 Journalist Ray Moynihan claims 
pharmaceutical industry has created 
a financial market by redefining 
normal variations in sexual desire as 
diseases. 
Moynihan (2005) The 
marketing of a disease: female 
sexual dysfunction.  
2006 Intrinsa approved by the European 
Medicines Agency for surgically 
post-menopausal women with 
Hypoactive Desire Disorder.  
Virus Inc. develop Alista 
testosterone to treat low desire in 
 
 31 
women but drug fails during trials. 
Boehringer Ingelheim discover 
during trials of an antidepressant 
(Flibanserin) that it potentially 
enhances libido for women. 
2007   
2008 A number of papers are published 
noting the prevalence of Hypoactive 
Sexual Desire Disorders 
 
Nappi et al. (2008) 
Management of hypoactive 
sexual desire disorder in 
women: current and emerging 
therapies. 
Shifren et al. (2008) Sexual 
problems and distress in 
United States women: 
Prevalence and correlates.  
2009 Boehringer Ingelheim files drug 
application for Flibanserin (aka 
Girosa) with FDA. 
Off label prescriptions for 
testosterone for women with 
Hypoactive Sexual Desire Disorder 
are recorded despite no standard 
guidance on appropriate 




Snabes & Simes (2009).  
Commentary: Approved 
hormonal treatments for 
HSDD: An unmet medical need.  
 32 
2010 Flibanserin is rejected in June by 
FDA advisory panel after trials show 
drug performs no better than 
placebo. Following this, in October 
Boehringer Ingelheim discontinues 
its development of the drug. 
 
2011 Sprout Pharmaceuticals acquires 
Flibanserin. 
Female Sexual Dysfunction 
(including Hypoactive Sexual Desire 
Disorder) is described by the FDA as 
one of 20 core “unmet medical 
needs” that have no safe/proven 
treatments. 
Libigel – trials on a testosterone gel 
for surgically menopausal women 
developed by BioSante. 
Pharmaceuticals are discontinued 
when it performs no better than 
placebo in trials. 
 
2012 Transparency Market Research 
estimates the global erectile 
dysfunction market (including 
Viagra, Cialis, Stendra/Spedra, 
 
 33 
Levitra, Staxyn, MUSE, Zydena, Mvix 
and Helleva) is worth $4.3 billion. 
European drug marketer for 
Intrinsa withdraws the drug citing 
‘commercial reasons’. 
2013 Hypoactive Sexual Desire Disorder 
is deleted from the DSM-5 and a 
new disorder-Female Sexual 
Interest/Arousal Disorder- added. 
FSAID requires that 3 of 6 possible 
symptoms be present for at least 6 
months and cause clinically 
significant distress. Stresses need to 
assess relationship problems, 
medical, cultural, religious factors, 
partner difficulties, body image and 
existing physical or mental health 
problems. 
Sprout pharmaceuticals reapply to 
the FDA following additional data 
collected on Flibanserin. FDA rejects 
application requesting further 
studies due to risks of side effects 
(somnolence, fainting, dizziness, 
IsHak & Tobia (2013) DSM-5 
changes in diagnostic criteria 
of sexual dysfunctions.  
 34 
exhaustion and nausea) plus 
unknown long-term effects. 
Concerns outweigh the modest 
benefit over unknown long-term 
effects. Sprout later appeal this and 
apply for a formal Dispute 
Resolution with the FDA. ISSWSH 
sends a petition signed by 4000 
people to the FDA. The FDA’s 
recommendation for more research 
stands.  
2014 In April a collective of health 
organisations, including the New 
View Campaign, Our Bodies 
Ourselves, the National Women’s 
Health Network and the American 
Medical Women’s Association, write 
to the FDA’s Director requesting the 
FDA reject Flibanserin on the 
grounds that risks outweigh any 
minimal benefits.  
Two months later, on June 24, 
health and women’s groups, backed 
by Sprout Pharmaceuticals 
 
 35 
introduce ‘Even The Score’ 
campaign and accuse the FDA of 
‘persistent gender inequality’ 
regarding treatment of sexual 
problems in women. 
October 2014: FDA holds a two-day 
hearing on 27-28th Oct. on the 
‘unmet medical need’ for treatment 
of FSD, with the first day a ‘patient 
focused’ event. There were some 
activists in the public comments 
section at the end of the meeting 
when anyone wishing to contribute 
was given two minutes. The people 
who spoke in this section were: 
Leonore Tiefer; Alessandra Hirsch 
from PharmedOut; Thea Cacchioni; 
Sidney Wolfe from the Health 
Researchers Group; Rebecca 
Holliman from PharmedOut; Judy 
Segal who was funded by the Social 
Sciences Humanities Research 
Counsel; Coco Jervis from the 
National Women’s Health Network, 
 36 
speaking on behalf of Ashland; 
Kimberley, a member of the public 
who “viewed myself as a potential 
patient”; Sally Greenburg, Executive 
Director of the National Consumers 
League; Deborah Arrindell from the 
American Sexual Health Association; 
Susan Scanlan, Chair Emeritus of the 
National Council of Women’s 
Organizations; Beth Battaglino, CEO 
of healthywomen.org; Sue Goldstein; 
Amanda and her husband Ben who 
wanted a pharmaceutical treatment 
(Ben was the only male member of 
the audience who spoke); and 
Michelle King Robson of 
EmpowHER.com.  
2015 February: Sprout resubmits 
Flibanserin, including the additional 
safety studies requested. They cited 
three trials that show that between 
46 and 60 percent of the women 
involved responded to the drug, and 
that levels of desire and the number 
 
 37 
of satisfying sexual events 
increased, and distress levels 
decreased, at rates modestly higher 
than placebo. 
March: Even the Score 
announces 11 members of 
Congress have written FDA 
Commissioner Margaret Hamburg 
to urge the approval of Flibanserin, 
in addition to earlier pleas from five 
other lawmakers. All are Democrats. 
June 1: An Even the Score online 
petition appears on change.org to 
change "#HERstory," urging the FDA 
approve flibanserin, garners more 
than 60,000 signatures. A New View 
online petition on change.org urging 
the FDA to reject flibanserin garners 
652 supporters. 
June 4: An FDA advisory committee 
votes 18-6 to recommend the FDA 
approve flibanserin for 
premenopausal women with 
conditions – a risk evaluation and 
 38 
mitigation strategy, including 
warnings not to take the drug with 
anti-fungal medications or alcohol.  
June 5: The stock price of Palatin 
Technologies, manufacturers of 
another female desire medication 
seeking FDA approval, soars 46 
percent, Business Insider reports. 
August 18: FDA approves 
Flibanserin (Addyi). The following 
day Valeant Pharmaceuticals 
acquired Sprout Pharmaceuticals for 
$500 million in cash initially and 
another $500 million in the first 
quarter of 2016. 
August 20: Sale of Sprout 
Pharmaceuticals to Valeant 
Pharmaceuticals announced. 
Valeant stock price drops 6%, New 
York Times reports. 
Valeant states it will make back 
investment if sales are $200 million, 
but potential sales could be greater. 
October 16: Addyi becomes 
 39 
available on prescription. There are 
a reported 227 prescriptions issued 




2016 JAMA publish research overviewing 
the efficacy of Addyi, find it 
ineffective compared to placebo 
while an editorial notes problems 
with the FDA hearings. 
Jaspers et al. (2016) Efficacy 
and safety of Flibanserin for 
the treatment of hypoactive 
sexual desire disorder in 
women: A systematic 
review and meta-analysis.  
 
Woloshin  & Schwartz 
(2016) US Food and Drug 
Administration approval of 
Flibanserin: Even the Score 
does not add up. 
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